Camurus appoints Jonas Duborn as Head of Compliance
Camurus is welcoming Jonas Duborn as the company’s new Head of Compliance, Europe and Australia, starting 30 June. In his role, Jonas will be responsible for leading and driving the implementation of a cohesive and consistent compliance strategy and have a key role in the management of a robust compliance program at Camurus – tailored to meet any evolving risks as the company continues to grow.
Jonas brings more than 10 years of experience from different roles within the compliance field. Most recently he held the position as Compliance Officer at LIF, the Swedish research-based pharmaceutical industry association. Previous work experiences include positions as Compliance Director and Compliance Manager at Sobi, Novartis and Amgen. Jonas has also been a board member of the Swedish Anticorruption Institute, IMM.
“Camurus attracted me as a great opportunity to join a Swedish based pharmaceutical company with an interesting product portfolio and great potential, in the midst of an exciting company journey.”, says Jonas. “I am looking forward getting to know my new colleagues both in Lund and across all regional offices and to further strengthen the compliance framework at Camurus.”
The appointment of Jonas as Head of Compliance enhances Camurus’ focus on responsible business – one of the key pillars in Camurus’ sustainability work. Camurus works to ensure that good business practice and ethics permeate the business and is integrated throughout the full value chain. This includes among other areas the work against corruption and anticompetitive behavior, protection of privacy, as well as transparency, relevance and accuracy in all collaborations with key stakeholders, including patient organizations, healthcare professionals and officials.
Learn more about Camurus’ focus on responsible business in Camurus Annual Report 2021, available on www.camurus.com.
Camurus is a Swedish science-led biopharmaceutical company committed to developing and commercializing innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal® drug delivery technologies and its extensive R&D expertise. Camurus’ clinical pipeline includes products for the treatment of cancer, endocrine diseases, pain and addiction, which are developed in-house and in collaboration with international pharmaceutical companies. The company’s shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com.